CN109125376A - 一种防治旋毛虫病的药物 - Google Patents
一种防治旋毛虫病的药物 Download PDFInfo
- Publication number
- CN109125376A CN109125376A CN201811285275.9A CN201811285275A CN109125376A CN 109125376 A CN109125376 A CN 109125376A CN 201811285275 A CN201811285275 A CN 201811285275A CN 109125376 A CN109125376 A CN 109125376A
- Authority
- CN
- China
- Prior art keywords
- seed
- cowherb
- agent
- drug
- butanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 229940079593 drug Drugs 0.000 title claims abstract description 22
- 230000002265 prevention Effects 0.000 title claims abstract description 6
- 244000178320 Vaccaria pyramidata Species 0.000 claims abstract description 37
- 235000010587 Vaccaria pyramidata Nutrition 0.000 claims abstract description 37
- 239000002021 butanolic extract Substances 0.000 claims abstract description 28
- GYIKGLVKALOGDP-DSBKMWIDSA-N Isovitexin 4'-O-glucoside 2''-O-arabinoside Natural products O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1c1c(O)c2C(=O)C=C(c3ccc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)cc3)Oc2cc1O)[C@@H]1[C@H](O)[C@H](O)[C@H](O)CO1 GYIKGLVKALOGDP-DSBKMWIDSA-N 0.000 claims abstract description 17
- GYIKGLVKALOGDP-HLEFUGOVSA-N Vaccarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C=2OC3=CC(O)=C([C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O[C@H]4[C@@H]([C@@H](O)[C@@H](O)CO4)O)C(O)=C3C(=O)C=2)C=C1 GYIKGLVKALOGDP-HLEFUGOVSA-N 0.000 claims abstract description 17
- GYIKGLVKALOGDP-UHFFFAOYSA-N Vaccarin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=C(C4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)CO4)O)C(O)=C3C(=O)C=2)C=C1 GYIKGLVKALOGDP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229930003519 erythroidine Natural products 0.000 claims abstract description 16
- 239000000463 material Substances 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 235000019441 ethanol Nutrition 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 238000005238 degreasing Methods 0.000 claims description 3
- 239000000469 ethanolic extract Substances 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 239000004909 Moisturizer Substances 0.000 claims description 2
- 239000002250 absorbent Substances 0.000 claims description 2
- 230000002745 absorbent Effects 0.000 claims description 2
- 239000002518 antifoaming agent Substances 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 239000006184 cosolvent Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000004088 foaming agent Substances 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- -1 microballoon Substances 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 230000001333 moisturizer Effects 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 229940100688 oral solution Drugs 0.000 claims description 2
- 230000003204 osmotic effect Effects 0.000 claims description 2
- 239000003961 penetration enhancing agent Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000004014 plasticizer Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 239000003380 propellant Substances 0.000 claims description 2
- 239000003340 retarding agent Substances 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000000375 suspending agent Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 abstract description 11
- 206010044608 Trichiniasis Diseases 0.000 abstract description 5
- 230000000749 insecticidal effect Effects 0.000 abstract description 5
- 208000003982 trichinellosis Diseases 0.000 abstract description 5
- 201000007588 trichinosis Diseases 0.000 abstract description 5
- 241001439624 Trichina Species 0.000 abstract description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 description 9
- 229960002669 albendazole Drugs 0.000 description 9
- 241000243774 Trichinella Species 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 206010048685 Oral infection Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000008236 heating water Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 244000070010 Erythrina variegata Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010034145 Helminth Proteins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 244000055346 Paulownia Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种防治旋毛虫病的药物,属于生物医药技术领域。本发明提供了一种获取简单、可口服给药使用方便、能够有效防治旋毛虫的杀虫药物王不留行正丁醇提取物,其中有效成分王不留行黄酮苷的含量(重量分数)不少于15%,刺桐碱的含量不少于1.5%,该药物可以使患旋毛虫病的小鼠身上成虫减少79.53%,肌肉幼虫减少77.70%。这一发现对于开发安全有效的抗旋毛虫病新药物,具有巨大的应用价值。
Description
技术领域
本发明涉及一种防治旋毛虫病的药物,属于生物医药技术领域。
背景技术
旋毛虫病是一种世界范围的严重人畜共患病,通过消化未加工的未煮熟的粪便以及含有感染性旋毛虫幼虫的其他动物的肉进行传播和感染,约有120-150种哺乳动物可自然感染此虫,尤其是猪、犬、猫、狐和某些鼠类感染率较高。旋毛虫病不仅直接危害养猪业和肉类业的经济利益,而且严重危害人类健康。
阿苯达唑(ABZ)是治疗人类旋毛虫病的基本驱虫剂。然而,其不溶于水,吸收缓慢限制了它们的吸收和生物利用度。此外,三岁以下儿童和孕妇禁用阿苯达唑。因此,目前迫切需要开发安全有效的抗旋毛虫病新药物,特别是那些副作用小,耐受性高的中药提取物。
发明内容
本发明的第一个目的是提供王不留行正丁醇提取物在制备防治旋毛虫病的药物中的应用,所述王不留行正丁醇提取物中王不留行黄酮苷的含量不少于15%,王不留行刺桐碱的含量不少于1.5%。
在本发明的一种实施方式中,所述药物中包含王不留行正丁醇提取物、药物载体和/或药用辅料。
在本发明的一种实施方式中,所述药物载体包含微囊、微球、纳米粒以及脂质体。
在本发明的一种实施方式中,所述药用辅料包含赋形剂以及附加剂。
在本发明的一种实施方式中,所述药用辅料包含溶剂、抛射剂、增溶剂、助溶剂、乳化剂、着色剂、黏合剂、崩解剂、填充剂、润滑剂、润湿剂、渗透压调节剂、稳定剂、助流剂、矫味剂、防腐剂、助悬剂、包衣材料、芳香剂、抗黏合剂、整合剂、渗透促进剂、pH值调节剂、缓冲剂、增塑剂、表面活性剂、发泡剂、消泡剂、增稠剂、包合剂、保湿剂、吸收剂、稀释剂、絮凝剂与反絮凝剂、助滤剂以及释放阻滞剂。
在本发明的一种实施方式中,所述附加剂包含微晶纤维素、羟丙基甲基纤维素以及精制卵磷脂。
在本发明的一种实施方式中,所述药物的剂型包括颗粒剂、胶囊剂、片剂、丸剂和口服液。
在本发明的一种实施方式中,所述王不留行正丁醇提取物应用的产品形式包含药物制剂、食品、营养品以及保健品。
本发明的第二个目的是提供一种防治旋毛虫病的药物,所述药物中包含王不留行正丁醇提取物,所述王不留行正丁醇提取物中王不留行黄酮苷的含量不少于15%,王不留行刺桐碱的含量不少于1.5%。
本发明的第三个目的是提供上述药物的制备方法,所述方法包括:称取炒王不留行种子,粉碎后经石油醚脱脂,然后用10倍(质量)的70%乙醇85℃水浴加热回流提取2h,减压浓缩得70%乙醇提取物,待挥发至无乙醇气味后,混悬于水中依次用乙酸乙酯和水饱和正丁醇萃取2次;合并水饱和正丁醇相,减压浓缩至干,去离子水复溶,真空干燥得王不留行正丁醇相干粉,经HPLC检测其中王不留行黄酮苷的含量(重量分数)不低于15%,刺桐碱的含量不低于1.5%。
本发明的有益效果:
本发明通过制备王不留行黄酮苷的含量不少于15%且王不留行刺桐碱的含量不少于1.5%的王不留行正丁醇提取物,并将其应用于感染旋毛虫的小鼠,通过喂食,发现王不留行正丁醇提取物可使成虫减少79.53%,肌肉幼虫减少77.70%。而且,该王不留行正丁醇提取物还具备一定的水溶性,比旋毛虫病的常用药物阿苯达唑(ABZ)更易被吸收利用。这一发现对于开发安全有效的抗旋毛虫病新药物,具有巨大的应用价值。
具体实施方式
(一)HPLC检测王不留行黄酮苷和刺桐碱含量的方法:
将正丁醇提取物干粉溶解于甲醇中备用。使用色谱柱AgilentC18柱(4.6mm×250mm,5μm);流动相使用甲醇-0.3%磷酸溶液;流速设为0.8mL/min;检测波长设为280nm;柱温设为30℃;进样量设为15μL。依次检测王不留行黄酮苷和刺桐碱标准品,然后检测正丁醇提取物干粉中王不留行黄酮苷和刺桐碱的含量。
实施例1:王不留行正丁醇提取物的制备
取100g炒王不留行种子,粉碎后经石油醚脱脂。然后用10倍(质量)的70%乙醇85℃水浴加热回流提取2h,减压浓缩得70%乙醇提取物,待挥发至无乙醇气味后,混悬于水中依次用乙酸乙酯和水饱和正丁醇萃取2次。合并水饱和正丁醇相,减压浓缩至干,去离子水复溶,真空干燥得王不留行正丁醇相干粉,经HPLC检测其中王不留行黄酮苷的含量(重量分数)不低于15%,刺桐碱的含量不低于1.5%。
实施例2:王不留行正丁醇提取物的杀虫药物药效评估
用300只旋毛虫幼虫口服感染6周龄ICR实验小鼠,感染旋毛虫的小鼠随机分为3组:Ⅰ组:感染非治疗组(即对照组,n=12,n为小鼠数量);Ⅱ组(肌肉期,n=12):从感染后第7天开始口服给药王不留行正丁醇提取物,并持续14天;Ⅲ组(肌肉期,n=12):从第7天开始接受ABZ给药并持续14天(Ⅱ组、Ⅲ组的用药量相同)。分别在第7天和第40天通过颈脱位处死小鼠6只。获得肌肉样品对旋毛虫成虫和幼虫进行计数统计。结果如表1所示。
表1王不留行正丁醇提取物的杀虫药物药效评估
在小鼠被感染后第7天和第40天我们对旋毛虫成虫和肌肉中幼虫的寄生虫数量进行了统计。结果表明,与对照组相比,王不留行正丁醇提取物和ABZ处理组成虫分别下降79.53%和81.22%,肌肉幼虫减少77.70%和90.70%。因此,王不留行正丁醇提取物是一种有效的用于防治旋毛虫病的药物,并且可能还是一种潜在的用于治疗由旋毛虫感染引起的炎症和相关疾病的有效药物。
另外,在20℃下我们测定了所得王不留行正丁醇提取物在100g水中达到饱和状态时所溶解的质量3.43g,即溶解度为3.43g。与阿苯达唑相比,本发明所提供的王不留行正丁醇提取物溶解度从0.3g提高到3.43g。这说明王不留行正丁醇提取物比阿苯达唑更易吸收,生物利用度更高,且王不留行正丁醇提取物作为中药提取物,其应用范围更广。
对比例1:王不留行黄酮苷和刺桐碱的杀虫药物药效评估
用300只旋毛虫幼虫口服感染6周龄ICR实验小鼠,感染旋毛虫的小鼠随机分为3组:Ⅳ组(肌肉期,n=12):从感染后第7天开始口服从王不留行正丁醇提取物中分离到的王不留行黄酮苷,并持续14天;Ⅴ组(肌肉期,n=12):从第7天开始口服从王不留行正丁醇提取物中分离到的王不留行刺桐碱并持续14天;Ⅵ组(肌肉期,n=12):从第7天开始口服市售王不留行黄酮苷和市售王不留行刺桐碱的复合物(按照王不留行黄酮苷与刺桐碱质量比为10:1进行复配)并持续14天(Ⅱ组、Ⅲ、Ⅳ、Ⅴ、Ⅵ组的用药质量相同)。分别在第7天和第40天通过颈脱位处死小鼠6只。获得肌肉样品对旋毛虫成虫和幼虫进行计数统计,如表2所示。
结果表明,仅口服从王不留行正丁醇提取物中分离到的王不留行黄酮苷、仅口服从王不留行正丁醇提取物中分离到的王不留行刺桐碱、口服市售王不留行黄酮苷和市售王不留行刺桐碱质量比为10:1进行复配得到的复合物时,与对照组(Ⅰ组)相比,小鼠身上的旋毛虫成虫数量分别下降了18.27%、55.32%和54.31%,小鼠身上的旋毛虫幼虫数量分别下降了12.88%、37.56%和38.95%。
表2王不留行黄酮苷和/或刺桐碱的杀虫药物药效评估
虽然本发明已以较佳实施例公开如上,但其并非用以限定本发明,任何熟悉此技术的人,在不脱离本发明的精神和范围内,都可做各种的改动与修饰,因此本发明的保护范围应该以权利要求书所界定的为准。
Claims (10)
1.王不留行正丁醇提取物在制备防治旋毛虫病的药物中的应用,其特征在于,所述王不留行正丁醇提取物中包括含量不少于15%的王不留行黄酮苷和含量不少于1.5%的王不留行刺桐碱。
2.根据权利要求1所述的应用,其特征在于,所述药物中包含王不留行正丁醇提取物、药物载体和/或药用辅料。
3.根据权利要求2所述的应用,其特征在于,所述药物载体包含微囊、微球、纳米粒以及脂质体。
4.根据权利要求2或3所述的应用,其特征在于,所述药用辅料包含赋形剂以及附加剂。
5.根据权利要求4所述的应用,其特征在于,所述药用辅料包含溶剂、抛射剂、增溶剂、助溶剂、乳化剂、着色剂、黏合剂、崩解剂、填充剂、润滑剂、润湿剂、渗透压调节剂、稳定剂、助流剂、矫味剂、防腐剂、助悬剂、包衣材料、芳香剂、抗黏合剂、整合剂、渗透促进剂、pH值调节剂、缓冲剂、增塑剂、表面活性剂、发泡剂、消泡剂、增稠剂、包合剂、保湿剂、吸收剂、稀释剂、絮凝剂与反絮凝剂、助滤剂以及释放阻滞剂。
6.根据权利要求4所述的应用,其特征在于,所述附加剂包含微晶纤维素、羟丙基甲基纤维素以及精制卵磷脂。
7.根据权利要求1-6任一所述的应用,其特征在于,所述药物的剂型包括颗粒剂、胶囊剂、片剂、丸剂和口服液。
8.根据权利要求7所述的应用,其特征在于,所述王不留行正丁醇提取物应用的产品形式包含药物制剂、食品、营养品以及保健品。
9.一种防治旋毛虫病的药物,其特征在于,所述药物中包含王不留行正丁醇提取物,所述王不留行正丁醇提取物中王不留行黄酮苷的含量不少于15%,王不留行刺桐碱的含量不少于1.5%。
10.权利要求9所述药物的制备方法,其特征在于,所述方法包括:
(1)称炒王不留行种子,粉碎,脱脂;然后用10倍(质量)的70%乙醇,85℃加热回流提取2h,减压浓缩得70%乙醇提取物;
(2)待挥发至无乙醇气味后,混悬于水中依次用乙酸乙酯和水饱和正丁醇萃取2次,合并水饱和正丁醇相,减压浓缩至干,复溶,干燥,即得王不留行正丁醇相干粉。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811285275.9A CN109125376B (zh) | 2018-10-31 | 2018-10-31 | 一种防治旋毛虫病的药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811285275.9A CN109125376B (zh) | 2018-10-31 | 2018-10-31 | 一种防治旋毛虫病的药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109125376A true CN109125376A (zh) | 2019-01-04 |
CN109125376B CN109125376B (zh) | 2021-06-25 |
Family
ID=64806861
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811285275.9A Active CN109125376B (zh) | 2018-10-31 | 2018-10-31 | 一种防治旋毛虫病的药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109125376B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101744857A (zh) * | 2009-11-16 | 2010-06-23 | 深圳市药品检验所 | 小花鬼针草提取物及其制备方法和在制备抗前列腺疾病药物中的应用 |
CN104431347A (zh) * | 2014-09-30 | 2015-03-25 | 全椒县大地种植专业合作社 | 一种防治猪弓形体病的饲料添加剂 |
-
2018
- 2018-10-31 CN CN201811285275.9A patent/CN109125376B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101744857A (zh) * | 2009-11-16 | 2010-06-23 | 深圳市药品检验所 | 小花鬼针草提取物及其制备方法和在制备抗前列腺疾病药物中的应用 |
CN104431347A (zh) * | 2014-09-30 | 2015-03-25 | 全椒县大地种植专业合作社 | 一种防治猪弓形体病的饲料添加剂 |
Non-Patent Citations (4)
Title |
---|
SUN H等: "Vaccaria hypaphorine alleviates lipopolysaccharide-induced inflammation via inactivation of NFΚB and ERK pathways in Raw 264.7 cells", 《BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE》 * |
孟贺等: "王不留行中王不留行黄酮苷的分离与鉴定", 《中草药》 * |
朱雪雪等: "合欢皮总皂苷治疗旋毛虫感染小鼠的疗效观察", 《中国人兽共患病学报》 * |
蔡维维等: "王不留行中刺桐碱的分离鉴定及抗炎活性研究", 《天然产物研究与开发》 * |
Also Published As
Publication number | Publication date |
---|---|
CN109125376B (zh) | 2021-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101564376B (zh) | 癸氧喹酯固体分散体及其制备 | |
Mutoloki et al. | A comparative immunopathological study of injection site reactions in salmonids following intraperitoneal injection with oil-adjuvanted vaccines | |
JPH0347132A (ja) | 原虫性疾患の予防治療剤 | |
JP6600626B2 (ja) | 植物抽出物及び関連組成物を得るための方法 | |
CN103893258B (zh) | 含有广金钱草总黄酮的口服固体制剂及其应用 | |
CN104922176B (zh) | 一种野菊花提取物的应用 | |
EP1713491A1 (en) | Simarouba amara and/or momordica charantia extracts for the treatment of coccidiosis in poultry | |
CN101596246B (zh) | 乌梅提取物和酸枣仁提取物复方制剂及其制备方法和应用 | |
CN109078049A (zh) | 基于肉苁蓉的苯乙醇苷类物质的抗抑郁应用 | |
CN102696637A (zh) | 龙胆苦苷药物制剂及其在防治烟草花叶病毒病中的应用 | |
CN108014142A (zh) | 猴头菌提取物在制备防治阿尔茨海默症药物、保健品或食品中的应用 | |
CN101664437B (zh) | 一种治疗球虫病的中药及其制备方法和用途 | |
Goryacha et al. | A hepatoprotective activity of Galium verum L. extracts against carbon tetrachloride-induced injury in rats | |
Kheawfu et al. | Nanoemulsion: A suitable nanodelivery system of clove oil for anesthetizing Nile tilapia | |
CN109125376A (zh) | 一种防治旋毛虫病的药物 | |
CN102696638B (zh) | 獐牙菜苷药物制剂及其在防治烟草花叶病毒病中的应用 | |
CN106821995B (zh) | 三氯苯达唑制剂及其制备方法和应用 | |
CN106265628B (zh) | 槐属二氢黄酮g在制备杀灭鱼类体外寄生纤毛虫药物中的应用 | |
JP4484267B2 (ja) | ガン免疫賦活剤およびアレルギー免疫抑制剤 | |
TWI612968B (zh) | 南洋山蘇水萃物的用途 | |
KR20180052258A (ko) | 감태 추출물 또는 이로부터 분리한 플로로탄닌계 화합물을 유효성분으로 포함하는 인플루엔자의 예방 또는 치료용 조성물 | |
CN102198099B (zh) | 一种妥曲珠利干混悬剂及其制备方法 | |
CN106176616B (zh) | 兽用水溶性乙氧酰胺苯甲酯纳米粉、制备方法及应用 | |
RU2558922C1 (ru) | Антигельминтное средство и способ его получения | |
CN105541838B (zh) | 一种治疗肾结石的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |